Delivery Order SPE2DB25D9305-SPE2DB25FQAJC
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Xolair 300 mg/2 ml auto-injector prefilled syringes. The contract, valued at $6,848.92 with a firm fixed-price structure, was awarded on August 13, 2025, with an ultimate completion date of September 4, 2025. This delivery order carries no set-aside designation and will be performed at the company's Park...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $8,561.10 by the Defense Logistics Agency for the supply of Xolair 150 mg/ml autoinjector. This firm fixed-price delivery order, issued on May 30, 2025, with an ultimate completion date of June 23, 2025, was awarded without set-aside designation. The contract represents a single task order issued under DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $1,712.23 by the Defense Logistics Agency (DLA) for the supply of Xolair 300 mg/2 ml auto-injector vials. The delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's existing single-award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $1,712.22 by the Defense Logistics Agency (DLA) for the supply of Xolair 150 mg/ml auto-injectors. The delivery order, issued on September 12, 2025, with an ultimate completion date of October 3, 2025, carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on August 20, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials. The contract has a ceiling value of $85,611.50 with an ultimate completion date of September 11, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $28.3K by the Defense Logistics Agency's Medical Supply Chain on August 27, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. This firm fixed-price delivery order is scheduled for completion by September 18, 2025, with no set-aside designation applied. The award represents a discrete fulfillment under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at approximately $142,000 by the Defense Logistics Agency (DLA) for XOLAIR 150 mg/ml syringes. The contract is firm fixed-price with an ultimate completion date of September 16, 2025, and was awarded on August 25, 2025, without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $1,277.01 by the Defense Logistics Agency (DLA) on June 18, 2025, with an ultimate completion date of July 11, 2025. The contract covers the supply of Xolair 75 mg/0.5 ml auto-injector units and is structured as a firm fixed-price delivery order with no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $37,137.60 by the Defense Logistics Agency (DLA) on August 21, 2025. The delivery order, which carries no set-aside designation, is for Xolair 150 mg/ml syringes with an ultimate completion date of September 12, 2025. This award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,424.44 by the Defense Logistics Agency (DLA) on August 7, 2025, for the supply of XOLAIR 150 mg/ml autoinjector medication. The contract carries a firm fixed-price structure with an ultimate completion date of August 28, 2025, and was awarded without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- SPE2DB25D9305Indefinite Delivery Contract
- SPE2DB25D9305-SPE2DB25FQAJCDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Xolair 75 mg/0.5 mL auto-injector vials. The contract, valued at $1,277.01 with a firm fixed-price structure, is scheduled for completion by September 24, 2025. This delivery order was awarded without set-aside designation on September 3, 2025, and represents a continuation of DMS Pharmaceutical Group's substantial role in supplying pharmaceutical products to federal defense healthcare systems. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which is valued at approximately $500 million and remains valid through November 2026. The IDC enables the DLA to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide. Xolair (omalizumab) is a monoclonal antibody used in the treatment of moderate-to-severe allergic asthma, and this delivery order fulfills the agency's requirement for this specialized pharmaceutical product to support military health operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 9/3/25 |